Intensive care unit readmission in adult Egyptian patients undergoing living donor liver transplant: A single-centre retrospective cohort study

doi:10.4254/wjh.v14.i6.1150

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5533)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-5) series.

Item

Count

PDF

166

WORD

HTML

1441

Figures (1-2)

441

Tables (1-5)

414

Sum=2497

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

276

Download

940

Sum=1216

Publishing Process of This Article

Item

Count

Browse

329

Download

1491

Sum=1820

Jun 27, 2022 (publication date) through Apr 18, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Jun 27, 2022; 14(6): 1150-1161
Published online Jun 27, 2022. doi: 10.4254/wjh.v14.i6.1150

Table 2 Preoperative patients’ and donors’ characteristics (data were expressed as mean ± SD or number & percentage) (total N = 299)

		Total (N = 299), %		No ICU readmission (N = 268), %		ICU readmission (N = 31), %		Test statistic	P value
Age (years); mean ± SD (Range)		49.8 ± 8.6; (19.0 - 67.0)		49.4 ± 8.8; (19.0 - 67.0)		53.0 ± 5.1; (42.0 - 64.0)		3.381^a	0.001¹
Gender	Female	45	15.1	36	13.4	9	29.0	FE	0.032¹
Gender	Male	254	84.9	232	86.6	22	71.0	FE	0.032¹
BMI (Kg/m²); mean ± SD (Range)		28.4 ± 4.3; (18.5 - 52.9)		28.2 ± 4.0; (18.5 - 42.0)		29.4 ± 6.5; (20.6 - 52.9)		0.936^a	0.356
MELD score; Median [IQR] (Range)		16.0; [13.0 – 18.0] (6.0 - 29.0)		16.0; [13.0 -18.0] (6.0 - 29.0)		15.0; [12.0 – 20.0] (7.0 - 28.0)		0.538^b	0.590
Positive medical history		103	34.4	86	32.1	17	54.8	FE	1.000
	DM	79	26.4	66	24.6	13	41.9	4.282^c	0.039¹
	Hypertension	24	8.0	17	6.3	7	22.6	FE	0.006¹
	Bronchial asthma	3	1.0	2	0.7	1	3.2	FE	0.281
	IHD	4	1.3	4	1.5	0	0.0	FE	1.000
	Renal	2	0.7	0	0.0	2	6.5	FE	0.010¹
	Bilharziasis	2	0.7	2	0.7	0	0.0	FE	1.000
	Others	9	3.0	8	3.0	1	3.2	FE	1.000
Diagnosis	AIH	10	3.3	10	3.7	0	0.0	FE	0.606
	HCC	117	39.1	107	39.9	10	32.3	0.686^c	0.408
	PVT	37	12.4	34	12.7	3	9.7	FE	0.780
	Cryptogenic	32	10.7	29	10.8	3	9.7	FE	1.000
	ESLD	10	3.3	8	3.0	2	6.5	FE	0.278
	HCV	229	76.6	204	76.1	25	80.6	0.317^c	0.573
	HBV	11	3.7	11	4.1	0	0.0	FE	0.612
	BCS	2	0.7	2	0.7	0	0.0	FE	1.000
	PSC	2	0.7	2	0.7	0	0.0	FE	1.000
Encephalopathy		95	31.8	87	32.5	8	25.8	0.568^c	0.451
Creatinine clearance (mL/min); mean ± SD (Range)		88.7 ± 26.5; (10.0 - 172.0)		88.5 ± 25.8; (10.0 - 170.0)		90.4 ± 32.7; (16.0 - 172.0)		0.384^a	0.702
Serum creatinine (mg/dL); mean ± SD (Range)		0.97 ± 0.31; (0.30 - 2.40)		0.97 ± 0.32; (0.30 - 2.40)		0.96 ± 0.24; (0.50 - 1.30)		0.255^a	0.799
Serum Albumin gm/dL; mean ± SD (Range)		3.0 ± 0.5; (1.8 - 4.8)		3.0 ± 0.5; (1.8 - 4.8)		2.8 ± 0.5; (1.8 - 3.8)		1.428^a	0.154
Na mmol/L; mean ± SD (Range)		135.1 ± 5.2; (117.0 - 147.0)		135.1 ± 5.4; (117.0 - 147.0)		135.0 ± 3.6; (128.0 - 145.0)		0.137^a	0.891
Total bilirubin mg/dL; Median [IQR] (Range)		1.3; [0.8 - 1.9] (0.2 - 27.0)		1.3; [0.7 - 1.9] (0.2 - 27.0)		1.4; [1.1 - 1.9] (0.6 - 5.6)		1.270^b	0.204
Alkaline phosphatase IU/L; Median [IQR] (Range)		143.0; [97.0 - 221.0] (6.2 - 2369.0)		144.5; [97.0 - 231.5] (6.2 - 2369.0)		131.0; [98.0 - 167.0] (45.0 - 1410.0)		1.041^b	0.298
Donor age (years); mean ± SD (Range)		29.8 ± 6.3; (16.0 - 48.0)		30.0 ± 6.3; (16.0 - 48.0)		28.0 ± 5.9; (18.0 - 39.0)		1.731^a	0.084
Donor gender	Female	94	31.4	83	31.0%	11	35.5	0.263^c	0.608
Donor gender	Male	205	68.6	185	69.0%	20	64.5	0.263^c	0.608
Donor BMI (Kg/m²); mean ± SD (Range)		23.7 ± 2.6; (17.7 - 32.0)		23.8 ± 2.6; (17.7 - 32.0)		23.0 ± 2.3; (18.3 - 29.0)		1.545^a	0.124

^aIndependent samples T-test.

^bMann-Whitney test.

^cPearson’s Chi square test for independence.

¹Significant at P < 0.05. AIH: Autoimmune hepatitis; BMI: Body mass index; DM: Diabetes mellitus; FE: Fisher’s exact test; IQR: Interquartile range; N: Number; SD: Standard deviation; ICU: Intensive care unit; IHD: Ischemic heart disease; HCC: Hepatocellular carcinoma; PVT: Portal vein thrombosis; ESLD: End-stage liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus; BCS: Budd-Chiari syndrome; PSC: Primary sclerosing cholangitis.

Citation: Salah M, Montasser IF, El Gendy HA, Korraa AA, Elewa GM, Dabbous H, Mahfouz HR, Abdelrahman M, Goda MH, Bahaa El-Din MM, El-Meteini M, Labib HA. Intensive care unit readmission in adult Egyptian patients undergoing living donor liver transplant: A single-centre retrospective cohort study. World J Hepatol 2022; 14(6): 1150-1161
URL: https://www.wjgnet.com/1948-5182/full/v14/i6/1150.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i6.1150